||EPS - Basic
||Market Cap (m)
|Software & Computer Services
Craneware Share Discussion Threads
Showing 76 to 96 of 100 messages
|Good to see the CEO increasing their shareholding after such a rise - often they top slice:
20 September 2016 - Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, has been informed that Keith Neilson, CEO of the Company, yesterday purchased 5,388 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 1,200 pence per share.
Following this transaction, Mr. Neilson's beneficial interest in Craneware has increased to 3,509,518 Ordinary Shares, representing approximately 13.1% of the Company's issued Ordinary Share capital.|
|Absolutely. Great company that keeps on delivering... I've been with it for a few years now. And it's one of the few blues on my screen today.Perhaps I should listen to my wife more when she suggests companies to back!!|
|Agreed.Looking at it another way, and ignoring who pays for what, the people in the know (the insiders) believe that share options issued at today's prices are motivatonal...this seems to be a positive indicator of the future share price?|
|For sure nowhere near unreasonable given the options are at the present price.
In reverse order of acceptability:
1) Free options vesting now
2) Free options vesting soon with easy performance hurdles
3) Free options vesting further out with easy performance hurdles
4) Free options with challenging performance hurdles
5) Cheap options at a later date with easy performance hurdles
6) Cheap options at a later date with challenging performance hurdles
7) You're paid for doing the job. Get on with it. If you want shares, buy them yourself. If you won't, why should we?
|Yeah you are right, B, so I deleted my earlier post.
I don't see them as excessive, they are reasonably long term and not discounted to current market price. Maybe there will be disclosure of the the performance criteria in the annual accounts.|
I'm not sure why you would think that if you read the RNS.
|That's correct Ben, and I agree with you. However, I really don't think options criteria should be secretive. I won't buy the excuse that it's commercially sensitive information.
|I don't have a problem with share options when the beneficiary pays the current share price at some point in the future?? It worries me when they are free shares., but that isn't the case here, I think...|
|More options subject to unspecified performance criteria.
Maybe they just have to stay alive?
|Your views here please
CRW reports in sterling but most income I believe is in dollars
does this inflate the sterling income reported as a result of the sterling drop,
8% to 10%?|
|Can you post nw99? Thanks|
|Nice new buy Rec from Sharewatch over the weekend|
|Their revenue recognition policy means that sales growth doesn't reflect the underlying progress of the business. 113% renewals by $ value and long-term contracts means they'll be churning out 10% earnings growth for the foreseeable future.|
|This looks a bit toppy. Worth looking at a bit deeper I think.|
|Craneware (CRW) December Bear Trap Could Lead Back To 580p Zone - LSE:CRW News
Today, 10:17 AM
Perhaps what is most interesting about covering small caps on a daily basis is the way that in terms of recovery plays similar configurations crop up again - CRW
|from the Chairmans's statement of 16 September 2014
I am pleased to report that following a promising first half, the increased sales activity which had been building over prior years has resulted in a record sales performance for the Group during the year. The marketplace for our products is developing as we had anticipated, with sales now coming from both individual hospitals and larger hospital groups. This trend has continued in the first months of the new fiscal year and we expect this to continue in a positive manner in the year ahead. The strength of our business model, which spreads the value of each contract over its lifetime, is such that these sales successes are building a solid platform of future revenue on which the business will grow.
The total value of contracts signed in the year increased by 84% to $71.0m (FY13: $38.5m). In accordance with the Group's revenue recognition policy, the vast majority of the revenue from these sales will benefit future years. Revenues increased to $42.6m, adjusted EBITDA increased to $13.1m and adjusted EPS increased to 34.0 cents. The Group continued to benefit from strong operational cash flow, closing the period with a cash balance of $32.6m (30 June 2013: $30.3m).
We are now benefiting from the restructuring of the business in previous periods, achieving record sales and ensuring scalability and sustainability for the future. We continue to invest in our products and people to ensure that we remain at the forefront of this evolving sector of the US healthcare IT market, the world's largest IT industry. With the acquisition of Kestros Limited, an emerging technology player in the patient access market, after the year end, the Group is well positioned to develop solutions to address the ongoing consumerisation trend within healthcare on both sides of the Atlantic.
The market environment for the business remains positive. Craneware's growing product set addresses many of the problems facing US healthcare organisations and the Group is increasing in strategic importance to its customer base. I am pleased to report that we recruited Colleen Blye and Russ Rudish to the Board in November 2013 and August 2014 respectively. Colleen and Russ will be able to provide significant additional insight into the challenges facing US healthcare organisations.
With a quarter of US hospitals as customers, high levels of visibility over future revenue, a significantly strengthened operating structure and enhanced product set, we are confident in the ongoing success of the Group. "|
11 March 2014 - Craneware plc (AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, announces its unaudited results for the six months ended 31 December 2013.
Financial Highlights (US dollars)
-- Revenue increased 5% to $21.1m (H1 2013: $20.1m)
-- Adjusted EBITDA(1) increased 6% to $5.7m (H1 2013: $5.4m)
-- Profit before tax increased 7% to $4.8m (H1 2013: $4.5m)
-- Adjusted basic EPS increased 8% to 14.3 cents per share (H1 2013: 13.2 cents per share)
-- Cash at period end $30.6m (H1 2013: $28.6m and $30.3m at 30 June 2013)
-- Proposed interim dividend of 5.7p per share (H1 2013: 5.2p per share)
(1.) Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments, released deferred consideration and transaction related costs
-- Good sales performance driven by incremental increases in the number of deals, in the size of hospital groups, the overall deal size and the number of longer-term contracts
-- 2013 Best in KLAS Awards: Chargemaster Toolkit and Bill Analyzer
-- Good growth in InSight Audit supporting the 'Gateway Products' strategy
-- Supportive market environment - The Affordable Care Act, new billing models, healthcare consumerisation, RAC and third party payor audits, market consolidation and affiliations
-- Strong revenue visibility over the remainder of the year and beyond
Keith Neilson, CEO of Craneware commented:
"Craneware remains at the forefront of providing solutions to US healthcare providers so they can achieve the revenue integrity required to support improved patient care and outcomes. We have seen a continued increase in sales during the period, to progressively larger hospital groups. The US Healthcare market seems to be settling as strategies are developing to support the need for change and deal with the uncertainties of the Affordable Care Act. With a strong product suite, clear strategic direction and high levels of revenue visibility, we are confident of continued future growth."|
|sensible comment here
|That's what I've been wondering - it certainly looks like a leak of some sort. It's already getting to the stage where the company will have to make a statement.|
|Given their slightly chequered history with the stock market, the multiple vs US comparables and the 100% US nature of their business, it wouldn't surprise me if they were bought out.|